Skip to content
Information Technology, Medical Health Aged Care

Ascom launches Activity Monitoring solution, an innovative software for long-term care homes

Ascom 3 mins read
Ascom SmartSense software

Ascom Activity Monitoring is an end-to-end solution for long-term care that monitors and predicts a deterioration in the health of residents. Built on top of Ascom SmartSense, this state-of-the-art and fully interoperable software allows the integration of external sensors and monitors movements and wandering behaviour, detects potential falls, and monitors typical patterns of long-term care home residents. Ascom Activity Monitoring also optimises workflow efficiency for the caregivers while preserving residents' lifestyle, privacy and safety.

The Ascom Activity Monitoring solution is part of the company's strategy to address the growing market for smart solutions in the long-term care industry. According to studies by the United Nations, the number of people worldwide aged 65 and older is expected to rise to 1.5 billion by 2050, compared to 702 million in 20191. The number of people aged 80 years or older is expected to grow even faster.

What is the Ascom Activity Monitoring solution? 

With the Activity Monitoring solution, Ascom provides an end-to-end solution for long-term care. The Ascom SmartSense algorithm converts incoming sensor data into statuses and warnings as needed and enables caregivers to have a better and continuous health update of the resident, predict a health deterioration, and rapidly modify the care provided to prevent possible consequences. When paired with Ofélia or Unite, alarms can be customised to each resident’s needs and sent to the right person, to the right device, and at the right time. Since the Ascom Activity Monitoring system is based on open integration infrastructure, third-party sensors, smart cameras, or other smart sensors can be easily integrated. 

Ascom SmartSense meets regional and national regulatory criteria. 

How does it work? 

A variety of sensors are positioned thoughtfully across the residents' rooms. An infrared ceiling detector can track movement, a door detector senses wandering, and a mattress detector looks for potential falls. Caregivers may easily integrate the sensors that are most appropriate for a resident's needs and confirm the resident's condition by consolidating data from multiple sources and presenting an overview of the resident on a single dashboard. Dashboards are available to caregivers on a variety of devices, such as professional smartphones like Ascom Myco 4 smartphone and Ward computers.

Providing added value to residents and caregivers 

By observing residents' overall lifestyle patterns, caregivers can enhance the patient’s experience in terms of comfort, dignity preservation, and maintaining the resident's autonomy and privacy.

Caregivers can also predict how much staff and equipment will be needed, which improves timeliness and reduces costs. It is also possible to detect a deterioration in a resident's health at an early stage if their lifestyle deviates from the norm. Caregivers are also able to limit the number of rounds (particularly when patients are resting and do not want to be disturbed) and concentrate on the residents who need it the most at any given time, all thanks to the global view of the various statuses of residents on the ward in real-time (virtual round). 

The introduction of the Ascom Activity Monitoring solution addresses the growing market demand for smart solutions in the long-term care and home care industry given the increasing number of residents that are becoming more dependent, the shortage of staff, and cost-efficient budgets. The Ascom Activity Monitoring solution enhances outcomes through the digitisation of care. 





1., Page 5, Table 1

About us:

Ascom’s vision is a world where the right information moves people forward. Our mission is to put the right information in the right hands at the right time so that people can make the best possible decisions. Ascom is a global provider of communication and collaboration solutions for the acute care, long-term care, and enterprise sectors. Our solutions are based on intelligent integrations with software and hardware, that are open source and compatible with third-party solutions. Every second, our systems generate large amounts of data, which we turn into actionable information. This helps us to bring data to life for people in the toughest operational environments, ensuring smooth, complete, and efficient workflows.

Ascom is headquartered in Baar (Switzerland), has operating businesses in 19 countries, and employs around 1,400 people worldwide. Ascom registered shares (ASCN) are listed on the SIX Swiss Exchange in Zurich.




Contact details:


More from this category

  • Medical Health Aged Care
  • 24/06/2024
  • 17:07
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/06/2024
  • 16:20
National Rural Health Alliance

Community-led innovation to revolutionise healthcare access in rural Australia

The National Rural Health Alliance (the Alliance) is delighted that the Minister for Health and Aged Care, the Hon Mark Butler, has today announced…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 24/06/2024
  • 12:25
Jane Morgan Management

Imugene (ASX:IMU) Doses First Patient in Pioneering Phase 1 onCARlytics Trial

Sydney, Australia, 24 June 2024: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is thrilled to announce the dosing of the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. This groundbreaking trial, named OASIS, is being conducted at City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumors. The OASIS trial is a world-first, combining a CD19-expressing oncolytic virus with a CD19-targeting drug. The trial aims to recruit 40-45 patients with advanced solid cancers that have metastasized, with preliminary early combination data…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.